Knight Therapeutics Enters into Exclusive License Agreement with Supernus Pharmaceuticals for Qelbree® (viloxazine) in Canada
MONTREAL, Dec. 19, 2023 -- Knight Therapeutics Inc. , a pan-American specialty pharmaceutical company, announced today that it has entered into an exclusive license agreement with Supernus...